Slide 1: Investor Presentation Q2 FY17
Investor Presentation Q2 FY 17 9th Nov 2016 Investor Presentation: Q2 FY17 Confidential 1
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: Key priorities on track
Key priorities on track Key Priorities Status Progress 1 India business Significant growth in the quarter (21% y-o-y) with most therapies 1 to beat market outpacing market growth Leadership positions across key therapeutic areas EBITDA EBITDA margin for Q1 was 17% and has improved to 18% d
Slide 4: Financial Performance – Q2 FY 16-17
Financial Performance – Q2 FY 16-17 Q2 FY17 (Consolidated) Revenue Break-up Actuals vs Q2 FY 16 (Rs Cr) Total Income from 3,751 9% Operations Global Others,1 a) Domestic Sales 1,522 19% API, 3% 3% b) Int’l Sales 2,150 2% Emerging c) Other Operating India, 79 5% Mkts, Income 39% 23% EBITDA 681 -13% E
Slide 5: Financial Performance – H1 FY 16-17
Financial Performance – H1 FY 16-17 H1 FY17 (Consolidated) Revenue Break-up Actuals vs H1 FY (Rs Cr) 16 1 Global Others, Total Income from API, 3% 2% 7,401 1% Emerging Operations Mkts, a) Domestic Sales 3,027 12% 22% India, b) Int’l Sales 4,201 -6% 40% c) Other Operating Income 173 13% EBITDA 1,292
Slide 6: India (Rx + Gx) Sales and Key Business Highlights
India (Rx + Gx) Sales Q2 Y-o-Y H1 Y-o-Y Rs Cr Rs Cr 1600 1467 3500 21% 14% 1400 2929 1213 3000 2579 1200 2500 1000 2000 800 1500 600 400 1000 200 500 0 0 Q2 FY 16 Q2 FY 17 H1 FY 16 H1 FY 17 Key Business Highlights IMS MAT Sept'16 Therapy Area Growth% 79%Sept’16, domestic business showed continued
Slide 7: North America
North America Q2 Y-o-Y H1 Y-o-Y $ Mn $ Mn 99 208 198 74 34% 32% Base Business1 Q2 FY 16 Q2 FY 17 H1 FY 16 H1 FY 17 Key Business Highlights Base business growth of ~34% in dollar terms vs last year Launched 6 new products in the quarter; many of these products are already at double digit market s
Slide 8: ANDA Portfolio & Pipeline
ANDA1 Portfolio & Pipeline 214 Total 131 24 59 ANDAs ANDA Portfolio 140 120 38 100 80 50 60 8 40 5 24 3- 3 20 38 15 24 0 6 Approved ANDAs Tentatively Approved ANDAs Under Approval ANDAs 2 Cipla Ltd PEPFAR Invagen Partnered ANDAs 1 Does not include Vet product ANDAs 2 PEPFAR approved ANDAs can be com
Slide 9: South Africa
South Africa Q2 Y-o-Y H1 Y-o-Y ZAR Mn ZAR Mn 1200 2000 14% 1870 8% 966 1800 1636 1000 894 1600 800 1400 1200 600 1000 800 400 600 200 400 200 0 0 Q2 FY 16 Q2 FY 17 H1 FY 16 H1 FY 17 Key Business Highlights As per IMS MAT (Aug’16), growth of 15.4% in the private market vs 8.3% market growth; Cipla
Slide 10: Emerging Markets
Emerging Markets1 Q2 Y-o-Y H1 Y-o-Y $ Mn $ Mn 140 131 -4% 300 -7% 126 259 120 250 240 100 200 80 150 60 100 40 20 50 0 0 Q2 FY 16 Q2 FY 17 H1 FY 16 H1 FY 17 Key Business Highlights Emerging market territories within Sub-Saharan Africa continued growth momentum with ~23% revenue growth Decline of
Slide 11: Europe and API
Europe and API Europe Drop in sales attributable to country-specific $ Mn challenges in legacy and new B2B business 30 24 25 Transition from DTM to B2B in EU markets close 17 20 -29% to conclusion. 15 10 Profitability uptake to be driven through higher 5 margin products and leaner cost structu
Slide 12: To Recap, continued progress on key priorities
To Recap, continued progress on key priorities Key Priorities Q2 FY17 Progress Steady growth in base business; 6 new products launched in the quarter, many of which have already achieved double digit market share Accelerate scale-up Integration of InvaGen and Exelan businesses with Cipla clo
Slide 13: Thank you
Thank you Contact details: Alpesh Dalal E-Mail: Investor.Relations@cipla.com Investor Presentation: Q2 FY17 Confidential 13